| 3.51 -0.01 (-0.28%) | 09-15 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.1 | 1-year : | 10.74 |
| Resists | First : | 6.94 | Second : | 9.19 |
| Pivot price | 3.84  |
|||
| Supports | First : | 3.28 | Second : | 2.73 |
| MAs | MA(5) : | 3.53 |
MA(20) : | 4.26 |
| MA(100) : | 6.69 |
MA(250) : | 26.96 |
|
| MACD | MACD : | -0.6 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 11.1 |
D(3) : | 7.7 |
| RSI | RSI(14): 36.1 |
|||
| 52-week | High : | 141.5 | Low : | 3.28 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ LIMN ] has closed above bottom band by 31.7%. Bollinger Bands are 50.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.58 - 3.6 | 3.6 - 3.61 |
| Low: | 3.38 - 3.4 | 3.4 - 3.41 |
| Close: | 3.55 - 3.58 | 3.58 - 3.6 |
Liminatus Pharma, Inc. is an immuno-oncology firm, currently in its clinical development phase, dedicated to pioneering new treatments for cancer. The company's headquarters are located in La Palma, California.
Tue, 18 Aug 2026
Liminatus (NASDAQ: LIMN) turns to 1-for-50 split as Nasdaq listing hangs on $1 bid - Stock Titan
Wed, 29 Jul 2026
Liminatus Pharma (NASDAQ: LIMN) cites $2.5M equity in Nasdaq compliance review - Stock Titan
Wed, 22 Jul 2026
Samda Biolab discloses 5.1% Liminatus Pharma (LIMN) ownership position - Stock Titan
Tue, 14 Jul 2026
Form 13D/A Liminatus Pharma For: 14 July By Investing.com - Investing.com Nigeria
Tue, 14 Jul 2026
Liminatus Pharma (LIMN) investors Valetudo and Chris Kim report 9.6M-share stake - Stock Titan
Thu, 09 Jul 2026
Liminatus Pharma, Inc. Class A Common Stock (NASDAQ: LIMN) Stock Price, News & Analysis - Kalkine
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 1 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 33.7 (%) |
| Held by Institutions | 1.4 (%) |
| Shares Short | 207 (K) |
| Shares Short P.Month | 48 (K) |
| EPS | -24 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.27 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -95.7 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.03 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -4 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -0.15 |
| PEG Ratio | 0 |
| Price to Book value | 13.25 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.21 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|